Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 10/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | USP1 | O94782 | 6/20 | 0.35 |
| ▸ | DRD2 | P14416 | 1/20 | 0.34 |
| ▸ | DRD4 | P21917 | 1/20 | 0.34 |
| ▸ | DRD3 | P35462 | 1/20 | 0.34 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.33 |
| ▸ | RORC | P51449 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11895576 | 0.96 | CHRM1 (0.49) | CHRM1KDM4ELMNASMN1; SMN2USP1 | |
| SCHEMBL11894862 | 0.93 | CHRM1 (0.47) | CHRM1KDM4ELMNASMN1; SMN2USP1 | |
| SCHEMBL11895155 | 0.90 | CHRM1 (0.45) | CHRM1KDM4ELMNASMN1; SMN2USP1 | |
| SCHEMBL11895057 | 0.88 | CHRM1 (0.55) | CHRM1KDM4ELMNASMN1; SMN2USP1 | |
| SCHEMBL11894871 | 0.88 | CHRM1 (0.49) | CHRM1KDM4ELMNASMN1; SMN2USP1 | |
| SCHEMBL6912805 | 0.88 | CHRM1 (0.49) | CHRM1KDM4ELMNASMN1; SMN2USP1 | |
| SCHEMBL11954933 | 0.85 | CHRM1 (0.47) | CHRM1KDM4ELMNASMN1; SMN2USP1 | |
| SCHEMBL6911395 | 0.84 | CHRM1 (0.58) | CHRM1KDM4ELMNASMN1; SMN2USP1 | |
| SCHEMBL11895844 | 0.84 | CHRM1 (0.46) | CHRM1KDM4ELMNASMN1; SMN2USP1 | |
| SCHEMBL11954942 | 0.84 | CHRM1 (0.46) | CHRM1KDM4ELMNASMN1; SMN2USP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2490692-B1 | QUINOLINONE-PYRAZOLONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | MERCK SHARP & DOHME (US) | 2016-11-16 | — | — | EP | claimed |
| US-8895580-B2 | Quinolinone-pyrazolone M1 receptor positive allosteric modulators | MERCK SHARP & DOHME CORP. (US) | 2014-11-25 | — | — | US | claimed |
| US-20120196845-A1 | QUINOLINONE-PYRAZOLONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | MERCK SHARP & DOHME LLC | 2012-08-02 | — | — | US | claimed |
| EP-2490692-B1 | QUINOLINONE-PYRAZOLONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | MERCK SHARP & DOHME (US) | 2016-11-16 | — | — | EP | disclosed |
| EP-2490692-B1 | QUINOLINONE-PYRAZOLONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | MERCK SHARP & DOHME (US) | 2016-11-16 | — | — | EP | disclosed |
| US-8895580-B2 | Quinolinone-pyrazolone M1 receptor positive allosteric modulators | MERCK SHARP & DOHME CORP. (US) | 2014-11-25 | — | — | US | disclosed |
| US-8895580-B2 | Quinolinone-pyrazolone M1 receptor positive allosteric modulators | MERCK SHARP & DOHME CORP. (US) | 2014-11-25 | — | — | US | disclosed |
| US-8895580-B2 | Quinolinone-pyrazolone M1 receptor positive allosteric modulators | MERCK SHARP & DOHME CORP. (US) | 2014-11-25 | — | — | US | disclosed |
| US-20120196845-A1 | QUINOLINONE-PYRAZOLONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | MERCK SHARP & DOHME LLC | 2012-08-02 | — | — | US | disclosed |
| US-20120196845-A1 | QUINOLINONE-PYRAZOLONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | MERCK SHARP & DOHME LLC | 2012-08-02 | — | — | US | disclosed |
| US-20120196845-A1 | QUINOLINONE-PYRAZOLONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | MERCK SHARP & DOHME LLC | 2012-08-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120196845-A1 | QUINOLINONE-PYRAZOLONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | CHRM1, OPRL1, CHRNA5 | CHRM1 1/4885KDM4E 1962/4885LMNA 4018/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.